AC Immune SA has published preclinical data on their TDP-43 PET tracer, ACI-19626, in Nature Communications. This tracer could revolutionize the diagnosis and treatment of neurodegenerative diseases like ALS, FTD, LATE, Alzheimer’s, and Parkinson’s, which share clinical features. The data shows high specificity and selectivity for TDP-43 aggregates, supporting potential use in patients. ACI-19626 is now in a Phase 1 clinical trial with results expected in Q4 2025. This advancement could lead to precision medicine approaches for neurodegenerative diseases, improving diagnosis and treatment outcomes. Nature Communications also published a commentary on the potential of TDP-43 PET tracers for biological diagnosis. AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission include key information and risk factors. Forward-looking statements are valid until new information or future developments arise. The company does not guarantee updates unless required by law. All forward-looking statements are subject to this cautionary statement.

Read more at 1. “Tesla announces record-breaking revenue in Q3 earnings report.” – CNBC
2. “Apple unveils new iPhone 13 models with improved cameras and longer battery life.” – Wall Street Journal
3. “Amazon Prime Day sales reach $11 billion, surpassing previous records.” – CNBC
4. “Facebook reveals plans to rebrand as Meta, focusing on metaverse technology.” – Reuters
5. “Google introduces new privacy features in latest Chrome browser update.” – Barchart: First Characterization of a TDP-43 PET Tracer Published in